BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 30146245)

  • 1. Talazoparib for BRCA-mutated advanced breast cancer.
    Gunjur A
    Lancet Oncol; 2018 Oct; 19(10):e511. PubMed ID: 30146245
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Mittra A; Coyne GHOS; Zlott J; Kummar S; Meehan R; Rubinstein L; Juwara L; Wilsker D; Ji J; Miller B; Navas T; Ferry-Galow KV; Voth AR; Chang TC; Jiwani S; Parchment RE; Doroshow JH; Chen AP
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):177-189. PubMed ID: 38010394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored targeted therapy for all: a realistic and worthwhile objective?
    Lønning PE
    Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S7. PubMed ID: 20030882
    [No Abstract]   [Full Text] [Related]  

  • 7. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the research progress of BRCA gene mutations in breast cancer.
    Wan A; Zhang G; Ma D; Zhang Y; Qi X
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188907. PubMed ID: 37172654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    Gruber JJ; Afghahi A; Timms K; DeWees A; Gross W; Aushev VN; Wu HT; Balcioglu M; Sethi H; Scott D; Foran J; McMillan A; Ford JM; Telli ML
    Nat Cancer; 2022 Oct; 3(10):1181-1191. PubMed ID: 36253484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    Chen MK
    FEBS J; 2021 May; 288(9):2884-2887. PubMed ID: 33570247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talazoparib in Patients With Solid Tumors With
    Srkalovic G; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Brouse G; Chan J; Mehmi I; Khalil M; Duvivier HL; Gaba A; Leuva H; Thota R; Yost KJ; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Jun; 8():e2400026. PubMed ID: 38865672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line PARP inhibition in ovarian cancer - standard of care for all?
    Banerjee SN; Lord CJ
    Nat Rev Clin Oncol; 2020 Mar; 17(3):136-137. PubMed ID: 32051558
    [No Abstract]   [Full Text] [Related]  

  • 13. Importance of
    Martínez-Galán J; Rodriguez I; Caba O
    World J Gastroenterol; 2021 Oct; 27(39):6515-6521. PubMed ID: 34754149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Altundag K
    Breast Cancer; 2023 Nov; 30(6):1107. PubMed ID: 37166624
    [No Abstract]   [Full Text] [Related]  

  • 15. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    Schweizer MT; Cheng HH; Nelson PS; Montgomery RB
    J Clin Oncol; 2020 Nov; 38(32):3740-3742. PubMed ID: 32897829
    [No Abstract]   [Full Text] [Related]  

  • 16. European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    Rutgers E; Balmana J; Beishon M; Benn K; Evans DG; Mansel R; Pharoah P; Perry Skinner V; Stoppa-Lyonnet D; Travado L; Wyld L
    Eur J Cancer; 2019 Jan; 106():45-53. PubMed ID: 30471647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper-Mediated Radiosynthesis of [
    Chen Z; Destro G; Guibbal F; Chan CY; Cornelissen B; Gouverneur V
    Org Lett; 2021 Sep; 23(18):7290-7294. PubMed ID: 34459606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Li J; Wen WX; Eklund M; Kvist A; Eriksson M; Christensen HN; Torstensson A; Bajalica-Lagercrantz S; Dunning AM; Decker B; Allen J; Luccarini C; Pooley K; Simard J; Dorling L; Easton DF; Teo SH; Hall P; Borg Å; Grönberg H; Czene K
    Int J Cancer; 2019 Mar; 144(5):1195-1204. PubMed ID: 30175445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.